Marksans Pharma Limited

Drug Manufacturers-General

Prices are adjusted according to historical splits.

Marksans Pharma Limited Stock Price


Today's Low:
Today's High:
Open Price:
52W Low:
52W High:
Prev. Close:

Company Statistics

Market Cap.:
₹49.78 billion
Book Value:
Revenue TTM:
₹19.18 billion
Operating Margin TTM:
Gross Profit TTM:
₹9.12 billion
Profit Margin:
Return on Assets TTM:
Return on Equity TTM:

Company Profile

Marksans Pharma Limited had its IPO on under the ticker symbol MARKSANS.

The company operates in the Healthcare sector and Drug Manufacturers-General industry. Marksans Pharma Limited has a staff strength of 852 employees.

Stock update

Shares of Marksans Pharma Limited opened at ₹109 at the start of the last trading session i.e. 2023-09-13.

The stocks traded within a range of ₹102.65 - ₹109, and closed at ₹105.9.

This is a -0.09% slip from the previous day's closing price.

A total volume of 447,354 shares were traded at the close of the day’s session.

In the last one week, shares of Marksans Pharma Limited have slipped by -3.86%.

Marksans Pharma Limited's Key Ratios

Marksans Pharma Limited has a market cap of ₹49.78 billion, indicating a price to book ratio of 2.0198 and a price to sales ratio of 1.5594.

In the last 12-months Marksans Pharma Limited’s revenue was ₹19.18 billion with a gross profit of ₹9.12 billion and an EBITDA of ₹3.48 billion. The EBITDA ratio measures Marksans Pharma Limited's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Marksans Pharma Limited’s operating margin was 16.38% while its return on assets stood at 9.38% with a return of equity of 17.76%.

In Q2, Marksans Pharma Limited’s quarterly earnings growth was a positive 4.1% while revenue growth was a positive 15.3%.

Marksans Pharma Limited’s PE and PEG Ratio

Forward PE
Trailing PE

Its diluted EPS in the last 12-months stands at ₹6.47 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Marksans Pharma Limited’s profitability.

Marksans Pharma Limited stock is trading at a EV to sales ratio of 1.3954 and a EV to EBITDA ratio of 7.0126. Its price to sales ratio in the trailing 12-months stood at 1.5594.

Marksans Pharma Limited stock pays annual dividends of ₹0 per share, indicating a yield of 0% and a payout ratio of 7.61%.

Balance sheet and cash flow metrics

Total Assets
₹21.90 billion
Total Liabilities
₹3.41 billion
Operating Cash Flow
Capital Expenditure
Dividend Payout Ratio

Marksans Pharma Limited ended 2024 with ₹21.90 billion in total assets and ₹0 in total liabilities. Its intangible assets were valued at ₹21.90 billion while shareholder equity stood at ₹17.45 billion.

Marksans Pharma Limited ended 2024 with ₹0 in deferred long-term liabilities, ₹3.41 billion in other current liabilities, 453160000.00 in common stock, ₹17.00 billion in retained earnings and ₹384.89 million in goodwill. Its cash balance stood at ₹3.82 billion and cash and short-term investments were ₹7.19 billion. The company’s total short-term debt was ₹415,880,000 while long-term debt stood at ₹0.

Marksans Pharma Limited’s total current assets stands at ₹16.75 billion while long-term investments were ₹0 and short-term investments were ₹41.95 million. Its net receivables were ₹4.17 billion compared to accounts payable of ₹2.31 billion and inventory worth ₹4.85 billion.

In 2024, Marksans Pharma Limited's operating cash flow was ₹0 while its capital expenditure stood at ₹0.

Comparatively, Marksans Pharma Limited paid ₹0.08 in dividends in 2024.

Other key metrics

Current Trading Price
52-Week High
52-Week Low
Analyst Target Price

Marksans Pharma Limited stock is currently trading at ₹105.9 per share. It touched a 52-week high of ₹122.5 and a 52-week low of ₹122.5. Analysts tracking the stock have a 12-month average target price of .

Its 50-day moving average was ₹109.12 and 200-day moving average was ₹80.5 The short ratio stood at 0 indicating a short percent outstanding of 0%.

Around 4399.3% of the company’s stock are held by insiders while 1545.8% are held by institutions.

Frequently Asked Questions About Marksans Pharma Limited

The stock symbol (also called stock or share ticker) of Marksans Pharma Limited is MARKSANS

The IPO of Marksans Pharma Limited took place on

Similar Industry Stocks (Drug Manufacturers-General)

Last Price
SunOpta Inc. (STKL)
Sciplay Corp (SCPL)

Most Active

Last Price
Amyris Inc (AMRS)
Humbl Inc (HMBL)

Top Gainers

Last Price
Latch Inc (LTCHW)

Top Losers

Last Price


Marksans Pharma Limited, together with its subsidiaries, engages in the research and development, manufacturing, marketing, and sale of generic pharmaceutical formulations worldwide. The company offers products in the analgesics, benign prostatic hyperplasia, antidiabetic, epilepsy, anti-inflammatory, hyperparathyroidism, diabetes, antacids, neurology, cardiovascular, hormonal, oncology, gastroenterology, antidiabetic, pain management, gynecology, antifungal, antiulceratives, vitamins, dermatology, cephalosporins, injectables, anti-allergy, antibacterial, and hypertension therapeutic areas. Marksans Pharma Limited was incorporated in 1992 and is headquartered in Mumbai, India.